Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer

Over-expression of the HER2/neu receptor occurs in 20 to 30 percent of breast tumors and is linked to poorer prognosis. The HER2/neu expression status determines whether or not patient will receive trastuzumab-based treatment. In clinical practice, over-expression of HER2/neu is routinely identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Lian, Czerniecki, Brian J., Fitzpatrick, Elizabeth, Xu, Shuwen, Schuchter, Lynn, Xu, Xiaowei, Zhang, Hongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114390/
https://www.ncbi.nlm.nih.gov/pubmed/25089226
http://dx.doi.org/10.4172/2155-9929.1000151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114390/
https://www.ncbi.nlm.nih.gov/pubmed/25089226
http://dx.doi.org/10.4172/2155-9929.1000151

Ejemplares similares